SEC Tracker
Get the app

Vaxcyte PCVX

Vaxcyte reports positive trial results for VAX-31

Form
8-K
Filed
Importance
Routine
  1. Phase 3 OPUS-1 trial met all primary endpoints
  2. VAX-31 showed noninferiority to PCV20 and PCV21
  3. VAX-31 was well tolerated with similar safety profile
  4. Results support BLA submission in 2028

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Vaxcyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.